News and Announcements
Dimerix (ASX:DXB) releases positive results from Phase 2 Trial of DMX-200
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix (ASX:DXB) is a clinical stage Australian Biotechnology company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead phase II clinical program (DMX-200) targeting chronic kidney disease. The company has recently announced “positive safety and efficacy data” following the company’s 27 patient Phase 2a Proof of Concept.
KEY TAKEAWAYS:
- Phase 2a of clinical trial tests has meet the primary safety checklist and demonstrates the efficacy in a number of patients.
- 25% of patients achieved a greater than 50% reduction in proteinuria.
- 45% of patients attained the permission to continue ongoing treatment.
- Study data informs dosing of patients and targeting parameters to progress the DMX-200 Phase 2b study during 2017.
Associate Professor David Packham* , one of the Principal Investigators in the study and Director of the Melbourne Renal Research Group, said “These are very encouraging data. DMX-200, and its combination with existing best therapy, appears safe and was well tolerated. An incremental 50% fall in proteinuria is a ‘high bar’ to set in studies of this type and the observation of this efficacy endpoint in 25% of the patients certainly warrants further clinical investigation in a larger, more targeted, population.’
Dimerix CEO Kathy Harrison said, “We are delighted that this study has resulted in such positive outcomes. The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program. Given this is a “hard to treat” patient group, we now have a very strong indication that the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
